NCT05414903 Reading Outcomes in Children With Vestibular Loss
| NCT ID | NCT05414903 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Father Flanagan's Boys' Home |
| Condition | Vestibular Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2022-06-06 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2022-06-06 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Vestibular loss can co-occur with hearing loss causing dual sensory deficits. This project examines vestibular loss as a contributing factor to reading difficulties for children with hearing loss, where previously only the effects of hearing loss and subsequent language difficulties have been considered. These results are expected to influence the identification and habilitation of vestibular loss in children with hearing loss.
Eligibility Criteria
Inclusion Criteria: * Children will be required to have nonverbal problem-solving/intelligence scores within 1.5 SD of the mean (mean = 100, SD = 15, 1.5 SD of mean = 77 - 123). * Children with normal hearing must have thresholds ≤20 dB HL from 0.25 to 8 kHz. * Children with hearing loss must have pure-tone averages \> 65 dB HL. Exclusion Criteria: * Fail a vision screen at 20/30 * Have autism, blindness, or other optic disorders, cerebral palsy, significant neurologic involvement, uncorrectable vision problems, and intellectual disability. * Children with nonverbal problem-solving/intelligence scores \> 123 or \< 77 will be excluded. * Each participant's current medications will be reviewed. Children taking medications known to result in oculomotor slowing will be excluded (i.e., anti-depressants, vestibular suppressants, sedatives, etc).
Contact & Investigator
Kristen L Janky, PhD
PRINCIPAL INVESTIGATOR
Father Flanagan's Boys' Home
Frequently Asked Questions
Who can join the NCT05414903 clinical trial?
This trial is open to participants of all sexes, aged 7 Years or older, up to 18 Years, studying Vestibular Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05414903 currently recruiting?
Yes, NCT05414903 is actively recruiting participants. Contact the research team at kristen.janky@boystown.org for enrollment information.
Where is the NCT05414903 trial being conducted?
This trial is being conducted at Omaha, United States.
Who is sponsoring the NCT05414903 clinical trial?
NCT05414903 is sponsored by Father Flanagan's Boys' Home. The principal investigator is Kristen L Janky, PhD at Father Flanagan's Boys' Home. The trial plans to enroll 90 participants.